Study Stopped
Company's strategic reasons
Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients
HypoScore-2
1 other identifier
observational
10
1 country
1
Brief Summary
In the last decades the prevalence of allergies has reached epidemic proportions. 10 to 15% of the population suffers from cat allergy. Investigators perform this study in order to further investigate symptom records and their evaluation in cat allergic patients. Investigators primarily aim to better standardize the symptom recording of cat allergic persons under real-life conditions and to evaluate the effect of hypoallergenic cats on symptom strength.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 3, 2016
CompletedFirst Posted
Study publicly available on registry
November 8, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedMay 3, 2017
May 1, 2017
5 months
November 3, 2016
May 2, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Duration of provocation test under 2 different conditions
up to 9 weeks
Number of score Points resulting from symptom record
up to 9 weeks
fel d 1 concentration in cat dander
by collecting cat's fur
up to 9 weeks
fel d 1 concentration in the air
by means of electrostatic dust collectors papers
up to 9 weeks
Interventions
Subjects muss record their allergic symptoms after contact with their cats
Eligibility Criteria
Healthy male or female participants with age between 18 and 65 years who suffer from confirmed cat allergy. The participants have to own a cat in the house/flat where they live.
You may qualify if:
- Participant understands the nature, meaning and scope of the study.
- Signed Informed Consent after being informed.
- Male and Female patients 18 years to 65 years of age.
- Positive screening prick test (mean wheal diameter equal or greater 3 mm) when tested with already standardized cat allergen extract.
- Positive screening prick test (wheal diameter equal or greater 3mm) to Histamine dihydrochloride 10 mg/ml.
- Positive Scratch Test when tested with cat dander sample of participant's cat.
- Baseline symptoms with a severity of "1" in at least 2 different symptoms.
- Owner of a cat that lives in the same household.
- Cat will not have been washed in the 4 weeks before starting the test phase.
You may not qualify if:
- Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent
- Participation in another study with investigational drug within the 30 days preceding and during the present study
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Positive skin reaction in the prick test to negative control
- History of anaphylactic reaction to pet allergens
- Severe diseases influencing the results of the present study by discretion of the investigator
- Immunotherapy with fel d 1 / cat allergen preparation during the past two years
- Skin lesions and excessive hair-growth in the skin test areas
- Treatment with prohibited concomitant medications according to section 8.3 with the exception of medications with local effects which will not influence the results of the skin tests and the results of the other tests (testing period).
- The patient should not suffer from other respiratory allergies during this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Zurichlead
- Ottawa Allery Research Corporationcollaborator
Study Sites (1)
Ottawa Allergy Research Corporation (OARC)
Ottawa, Ontario, K1G 6C6, Canada
Study Officials
- STUDY DIRECTOR
Gabriela Senti Senti, Prof. Dr.
Hypo Pet AG, c/o University of Zurich
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2016
First Posted
November 8, 2016
Study Start
September 1, 2016
Primary Completion
February 1, 2017
Study Completion
February 1, 2017
Last Updated
May 3, 2017
Record last verified: 2017-05
Data Sharing
- IPD Sharing
- Will not share